prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Basal, Temporary Copy. Diagnosis. A. RIGHT BREAST, MASTECTOMY: - HIGH-GRADE INVASIVE DUCTAL CARCINOMA; SEE SYNOPTIC REPORT. - NEGATIVE MARGINS. - SKIN AND NIPPLE WITHOUT SIGNIFICANT PATHOLOGIC ABNORMALITY. - FOUR LYMPH NODES, NEGATIVE FOR TUMOR (0/4); SEE SPECIAL STAINS. (Electronic signature). Verified: Synoptic Report. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Greatest dimension of largest focus of invasion over 0.1 cm: 2.5 cm. Additional dimensions: 2.5 x 1.5 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: Skeietal muscle is present and is free of carcinoma. DUCTAL CARCINOMA IN SITU (DCIS): No DCIS is present. LOBULAR CARCINOMA IN SITU (LCIS): Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape,. occasionally with very large and bizarre forms. MITOTIC COUNT: Score 3. Number of mitoses per 10 high-power fields: 88. Diameter of microscope field: 0.55 mm. OVERALL GRADE: Grade 3: scores of 8 or 9. MARGINS: Margins uninvolved by invasive carcinoma. Distance from anterior margin: 4.0 mm. Distance from posterior margin: 2.0 mm. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE BREAST: No known presurgical therapy. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE LYMPH NODES: No known presurgical therapy. LYMPH-VASCULAR INVASION: Not identified. Temporary Copy. DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Total number of lymph nodes examined (sentinel and nonsentinel): 4. Number of lymph nodes with macrometastases (>0.2 cm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 0. METHOD OF EV /ALUATION OF SENTINAL LYMPH NODES: Hematoxylin and eosin (H&E), one level. Immunohistochemistry. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT2: Tumor >20 mm but less than or equal to 50 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN0: No regional lymph node metastasis identified histologically. DISTANT METASTASIS (M): Not applicable. ADDITIONAL PATHOLOGIC FINDINGS: Benign breast with calcifications. ESTROGEN RECEPTOR: Performed on this specimen. No immunoreactive tumor cells present. PROGESTERONE RECEPTOR: Performed on this specimen. No immunoreactive tumor cells present. HER2/NEU IMMUNOPEROXIDASE STUDIES: Performed on this specimen. Negative (Score 0). MICROCALCIFICATIONS: Present in non-neoplastic tissue. Specimen Source. A. RT Breast and Axillary Contents. Clinical Information. None. PRE-OP DIAGNOSIS: Right breast CA. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Right modified mastectomy. Gross Description. The specimen is labeled "RIGHT BREAST AND AXILLARY CONTENTS" and is received unfixed (the. specimen is in formalin for more than 6 hours and less than 48 hours). It consists of a 420 g right mastectomy. with axillary contents weighing 420 g measuring 18 x 10 x 3.0 cm. The axillary content measures 6.0 x 5.5 x 3.0. cm. The nipple is unremarkable measures 1.3 x 1.3 cm in maximum dimensions. Solar is unremarkable. The left. fascia is smooth and glistening. The anterior margin is inked red and the deep posterior margin is inked black. On sectioning, there is a well-circumscribed lobulated focally hemorrhagic pink-tan mass measuring 2.5 x 2.5 x. 1.5 cm. The mass is close to the deep posterior margin in the outer quadrant close to the axillary contents. The. mass is 0.7 cm from the anterior margin and approximately 12 cm from the nipple. On further sectioning the. breast parenchyma is nodular, there are no other lesions grossly identified. There are four fatty lymph nodes. Temporary Copy. ranging from 0.5-2.0 cm in maximum dimensions. Representative sections are submitted. Section Key: Al - A2 tumor markers with deep margin. A3 tumor. A4 - nipple and skin. A5 - anterior margin close to mass. A6 - upper inner quadrant. A7 - lower inner quadrant. A8 - random sections from central breast. A9 - upper outer quadrant. A10 - lower outer quadrant. All - one lymph node bisected. A12 - one lymph node bisected. A13 - two lymph nodes. Time specimen was removed from the patient (procedure time): Time specimen was placed in formalin: Ischemic time: 1 hour 20 minutes. Special Stains / Slides. IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN RECEPTORS, PROGESTERONE. RECEPTORS, AND HER-2NEU IN INVASIVE MAMMARY CARCINOMA . ESTROGEN RECEPTORS: 0 %, NEGATIVE. PROGESTERONE RECEPTORS: 0 %, NEGATIVE. STAINING INTENSITY: HER-2NEU: SCORE 0, NEGATIVE. Immunohistochemical studies were performed on formalin fixed paraffin embedded tissue (Block A2) using the. following monoclonal antibodies; Estrogen receptor (Clone SP1), Progesterone receptor (Clone 1E2) and. Her-2neu (. Clone 4B5); control sections for HER-2Neu are provided within a kit (score 0 MCF-7, score. 1+ T-47D, score 2+ MDA-MB-453, score 3+ BT-474). Detection system used: polymer. Primary antibodies,. reagents and control sections for HER-2neu are all provided by. All controls show appropriate reactivity. Reactivity of Estrogen and Progesterone receptors is determined based on the percentage of positively. stained nuclei of tumor cells. Reference values (CAP accreditation program checklist 2010 and guidelines on. webpage): Positive: nuclear staining in 1% or greater than 1% of invasive carcinoma cells. Negative : nuclear staining in less than 1% of invasive carcinoma cells. Staining intensity: is reported as weak, moderate or strong. Temporary Copy. HER-2neu reactivity is reported applying the CAP scoring guidelines (CAP accreditation program checklist. 2010 and guidelines on webpage): Score 0 = Negative: No immunoreactivity, or faint weak immunoreactivity in <10% of tumor cells but only a. portion of the membrane is positive.. Score 1 = Negative: Faint weak immunoreactivity in 10% or >10% of tumor cells but only a portion of the. membrane is positive. Score 2+ = Equivocal: Weak to moderate complete membrane immunoreactivity in >10% of tumor cells or. circumferential intense membrane staining in <30% of cells. Score 3+ = Positive: More than 30% of the tumor cells must show circumferential intense and uniform. membrane staining. A homogeneous (chicken wire) pattern should be present. Equivocal results for HER-2neu (Score 2+) will be subsequently followed by a reflex dual-color ISH testing. Additional immunohistochemical studies fpr AE1/AE3 were performed on formalin fixed, paraffin-embedded. tissue (Blocks A11-13) with adequate positive and negative control sections. All stains were negative. The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food. and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical. purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory. Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. Tissue Code.

expanded version (tokens=2380) : 
 This breast pathology report provides information on a high-grade invasive ductal carcinoma found in the patient's right breast, with no ductal carcinoma in situ or lobular carcinoma in situ identified. The subtype is basal. The tumor size is 2.5 x 1.5 cm, and there is a single focus of invasive carcinoma. Margins are uninvolved by invasive carcinoma, and lymphovascular invasion is not identified. The histological grade is Grade 3, with a score of 8 or 9. The tumor exhibits a glandular/tubular differentiation score of 3 (<10% of tumor area forming glandular/tubular structures) and high nuclear pleomorphism score of 3, with vesicular nuclei often having prominent nucleoli and exhibiting marked variation in size and shape. There is a high mitotic count score of 3, with 88 mitoses per 10 high-power fields. Four lymph nodes were examined and were negative for tumor. Receptor status shows negative immunoreactive tumor cells for both estrogen and progesterone receptors. HER2/neu immunoperoxidase studies show a negative score of 0. Microcalcifications are present in non-neoplastic tissue. There is no mention of necrosis or tumor infiltrating lymphocytes. Additional benign breast pathology includes calcifications. The specimen was obtained through a right modified mastectomy.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2540) : 
 This is a pathology report on a basal subtype high-grade invasive ductal carcinoma found in the patient's right breast. It is a 2.5 x 1.5 cm single focus tumor with no ductal carcinoma in situ or lobular carcinoma in situ identified. Four lymph nodes examined were negative for cancer. Receptor status shows negative immunoreactivity for estrogen and progesterone receptors, and HER2/neu immunoperoxidase studies indicate a negative score of 0. No mention of necrosis or tumor infiltrating lymphocytes was made.

